US 12,264,219 B2
Conductive benzoic acid based polymer containing biomaterial for enhancement of tissue conduction in vitro and in vivo
Ren-Ke Li, Toronto (CA)
Assigned to University Health Network, Toronto (CA)
Appl. No. 16/634,026
Filed by UNIVERSITY HEALTH NETWORK, Toronto (CA)
PCT Filed Jul. 27, 2018, PCT No. PCT/CA2018/050914
§ 371(c)(1), (2) Date Jan. 24, 2020,
PCT Pub. No. WO2019/018942, PCT Pub. Date Jan. 31, 2019.
Claims priority of provisional application 62/537,755, filed on Jul. 27, 2017.
Prior Publication US 2021/0087336 A1, Mar. 25, 2021
Int. Cl. C08G 69/48 (2006.01); A61L 31/04 (2006.01); A61L 31/06 (2006.01); A61L 31/14 (2006.01); A61L 31/16 (2006.01); A61N 1/05 (2006.01); A61N 1/375 (2006.01); C08L 89/06 (2006.01)
CPC C08G 69/48 (2013.01) [A61L 31/045 (2013.01); A61L 31/06 (2013.01); A61L 31/145 (2013.01); A61L 31/16 (2013.01); A61N 1/056 (2013.01); A61N 1/37512 (2017.08); C08L 89/06 (2013.01)] 18 Claims
 
1. A biocompatible conductive biomaterial comprising a conductive polymer and a biocompatible component, the conductive polymer comprising an aminomethoxybenzoic acid (AMBA) polymer, wherein the conductive polymer is covalently conjugated to the biocompatible component, wherein the conductivity of the biomaterial is greater than, at least or equal to about 10−6 S/cm and wherein the AMBA polymer consists of polymerized AMBA monomers.